Get started
Author

Filippo Mori

Observed name: F. Mori
Institution: Kedrion (Italy)
Observed institutions: University of Pisa, Istituto di Fisiologia Clinica, Regione del Veneto, Ideon Innovation (Sweden), National Research Council, Kedrion (Italy), Regione Emilia-Romagna, Centro Nazionale Sangue
ORCID: 0000-0001-8940-5415
Observed ORCID: 0000-0001-8940-5415
OpenAlex ID: A5017992138
A Novel Class of Highly Potent and Selective A1 Adenosine Antagonists: Structure−Affinity Profile of a Series of 1,8-Naphthyridine Derivatives
2000 · Pier Luigi Ferrarini, Claudio Mori, et al. · Journal of Medicinal Chemistry · 34
Post-translational modifications and antioxidant properties of different therapeutic human serum albumins
2021 · Filippo Mori, Letizia Natali, et al. · International Journal of Biological Macromolecules · 18
Therapeutic Solutions of Human Albumin – The Possible Effect of Process-Induced Molecular Alterations on Clinical Efficacy and Safety
2022 · Albert Farrugia, Filippo Mori · Journal of Pharmaceutical Sciences · 17
Doxorubicin coupled to lactosaminated albumin: Effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats
2008 · Giuseppina Di Stefano, Luigi Fiume, et al. · European Journal of Pharmaceutical Sciences · 15
Progress in large‐scale purification of factor VIII/von Willebrand factor concentrates using ion‐exchange chromatography
2008 · F. Mori, I. Nardini, et al. · Vox Sanguinis · 14
New approach for rapid detection of known hemoglobin variants using LC‐MS/MS combined with a peptide database
2006 · F. Basilico, D. Di Silvestre, et al. · Journal of Mass Spectrometry · 14
Characterization of factor VIII pharmaceutical preparations by means of MudPIT proteomic approach
2010 · Fabrizio Basilico, Ilaria Nardini, et al. · Journal of Pharmaceutical and Biomedical Analysis · 13
New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia
2024 · Alan Zanardi, Ilaria Nardini, et al. · Communications Biology · 9
PDF
Quality control of recovered plasma for fractionation: an extensive Italian study
2008 · Giuliano Grazzini, Giuseppe Rossi, et al. · Transfusion · 9
Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment
2023 · Lucia Vizzoni, Chiara Migone, et al. · Pharmaceutics · 8
PDF
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics
2020 · Anna Maria Piras, Ylenia Zambito, et al. · Pharmaceuticals · 7
PDF
Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test
2010 · Filippo Mori, Paola Rossi, et al. · Blood Coagulation & Fibrinolysis · 7
Condensation of substituted 2‐aminopyridine with β‐ketocarboxylic esters: 4H‐pyrido[1,2‐a]pyrimidin‐4‐ones and pyridin‐2‐ones
1999 · Pier Luigi Ferrarini, Claudio Mori, et al. · Journal of Heterocyclic Chemistry · 5
An unexpected result in the condensation of 2‐amino‐6‐bromopyridine with ethyl 4‐chloroacetoacetate: Four dihalo‐substituted pyrido[1,2‐a]pyrimidin‐4‐ones as reaction products
1999 · Pier Luigi Ferrarini, Claudio Mori, et al. · Journal of Heterocyclic Chemistry · 5
Proof of concept of a new plasma complement Factor H from waste plasma fraction
2024 · Filippo Mori, Giancarlo Pascali, et al. · Frontiers in Immunology · 4
A multianalytical approach to investigate the effect of nanofiltration on plasma-derived factor IX clinical lots
2018 · Rosita Russo, Giuseppina Focà, et al. · Analytical Biochemistry · 4
New plasma protein C and protein S concentrate: A synergy for therapeutic purposes
2023 · Filippo Mori, Cristina Angelini, et al. · Vox Sanguinis · 3
PDF
Characterization of a plasma‐derived double−viral‐inactivated factor VIII concentrate (antihaemophilic factor [human]): Focus on TTP treatment
2021 · Filippo Mori, Ilaria Nardini, et al. · Haemophilia · 3
ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura
2022 · Filippo Mori, Ilaria Nardini, et al. · Thrombosis Update · 2
PDF
Plasminogen–cyclodextrin aerosol for ARDS: activity retention in simulated oxygen therapy and inflammation-triggered clot lysis
2025 · Lucia Vizzoni, Chiara Migone, et al. · International Journal of Pharmaceutics · 1
Comparison among three different bleeding scores and the thrombin generation assay to assess the different hemorrhagic phenotypes in patients with FVII deficiency
2022 · Samantha Pasca, Cristina Santoro, et al. · Bleeding Thrombosis and Vascular Biology · 1
PDF
Intra‐ and interassay variations of two thrombin generation methods
2021 · Filippo Mori, Cristina Genuardo, et al. · International Journal of Laboratory Hematology · 1
Purification and characterization of a new highly pure, double virus inactivated von Willebrand factor concentrate
2017 · Filippo Mori, Marcella Maddaluno, et al. · Blood Coagulation & Fibrinolysis · 1
ChemInform Abstract: Condensation of Substituted 2‐Aminopyridine with β‐Ketocarboxylic Esters: 4H‐Pyrido[1,2‐a]pyrimidin‐4‐ones and Pyridin‐2‐ones.
2000 · Pier Luigi Ferrarini, Claudio Mori, et al. · ChemInform · 1
Evaluation of prophylactic polyclonal anti‐D antibodies: Differences in Fc‐glycosylation in commercial products
2021 · Filippo Mori, Alfonso Salvatore, et al. · Vox Sanguinis
Works count: 26
Citation count: 196
H-index: 9
I10-index: 7
Year
Topic
Type